Drug Database
EQ

equine antithymocyte globulin (Thymogam)

✓ Approved

Bharat Serums and Vaccines Limited · 多克隆抗体 · 多克隆抗体

什么是 equine antithymocyte globulin?

equine antithymocyte globulin 是一种多克隆抗体,由Bharat Serums and Vaccines Limited研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Thymogam
公司Bharat Serums and Vaccines Limited
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

equine antithymocyte globulin 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersAplastic anaemia✓ Approved
Immune system disordersSolid organ transplant rejection✓ Approved

相关研究文献

PubMedVeterinary medicine and science2026-11-19

Early Changes in Serum Protein Electrophoresis and Gamma Globulin during Initial 4 Weeks of Remdesivir Therapy in FIP Cats.

Khalili Kosar K, Cheraghi Hadi H, Saljooghian Isfahani Mohammad Hossein MH

Feline infectious peritonitis (FIP) is a fatal multisystem inflammatory disorder of cats that was historically considered untreatable before the emergence of direct-acting antivirals. The objective of the study was to evaluate early serial changes in serum protein electrophoresis (SPE) patterns in cats treated with remdesivir for FIP, emphasizing gamma-globulin concentrations and percentages. Animals included eighteen client-owned cats diagnosed with FIP based on clinical presentation, standard clinicopathological profiles, and confirmatory RT-PCR. Cats received remdesivir for 4 weeks and were monitored weekly through clinical examinations and laboratory evaluations. Blood samples were collected at baseline (prior to treatment initiation) and weekly for 4 weeks. The SPE analyzed the blood taken every week for the serum protein fractions, such as albumin and the different globulins, namely α1-, α2-, β1-, β2-, and γ-globulins. The albumin to globulin ratio (A/G ratio) was also determined. Gamma globulins were found to be significantly reduced from a median of 3.1 g/dL at week 2 to a median of 2.2 g/dL at the end of week 4 (p < .05) in cats that showed clinical response. Notably, ROC curve analysis identified that a gamma-globulin percentage <23% at week 4 and 18.96% by week 6 (AUC = 0.9105) was strongly associated with complete clinical recovery and sustained relapse-free remission. Serial monitoring of serum protein electrophoresis, particularly longitudinal trends in gamma-globulin percentages and the A/G ratio, provides an objective, practical biomarker strategy to evaluate treatment response and guide the safe timing of antiviral therapy cessation in cats with FIP.

PMID 43052221
阅读全文 →
PubMedVeterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association2026-11-19

Guttural Pouch Endoscopy Outperforms Radiography for Detection of Advanced Temporohyoid Osteoarthropathy Using Computed Tomography as the Reference Standard in 382 Horses.

Scheubeck Till T, Weber Lisa A LA, Ohnesorge Bernhard B, Rohn Karl K et al.

Temporohyoid osteoarthropathy (THO) is a chronic, non-septic disorder of the equine temporohyoid joint (THJ) that may lead to neurological dysfunction. Computed tomography (CT) has become the gold standard in the assessment of THO. This retrospective cross-sectional study aimed to compare the diagnostic performance of guttural pouch endoscopy and radiography with CT as the reference standard in horses with THO. Medical records and imaging data from 382 horses (764 THJ) were reviewed. All 382 horses underwent CT examination, with endoscopic examinations available either uni- or bilaterally, and radiographs performed in 107 of the 382 horses (28.0%). CT studies, radiographs, and endoscopic videos were blinded, reviewed, and graded by two observers. THO (CT grade ≥ 1) was identified in 147 horses (38.5%). Interobserver agreement was almost perfect for CT (prevalence- and bias-adjusted kappa [PABAK] = 0.89-0.93), moderate for endoscopic scoring (PABAK = 0.46-0.51), and almost perfect for radiographic evaluation (PABAK = 0.81-0.90). Sensitivity and specificity of guttural pouch endoscopy for the diagnosis of THO (CT Grade 3-5) were 81.3% (95% confidence interval [CI]: 67.7%-94.8%) to 84.9% (95% CI: 72.6%-97.1%), and 87.6% (95% CI: 83.8%-91.4%) to 90.7% (95% CI: 87.4%-94.0%), respectively. An endoscopic score ≥2 significantly correlated with CT-confirmed cases of moderate-to-severe THO. Radiography showed the lowest diagnostic accuracy and was limited to severe cases of THO. In conclusion, guttural pouch endoscopy is a valuable first-line examination for identifying advanced (CT Grade 3-5) THO. Radiography has limited diagnostic utility, and CT showed a high interobserver agreement.

PMID 43053570
阅读全文 →
PubMedHaematologica2026-11-19

Reduced intensity hematopoietic cell transplant using best available donor and post-transplant cyclophosphamide is safe and curative for transfusion-dependent thalassemia

Ktena Yiouli P YP, Burris Megan M, Berger Rebecca R, Duke Kathryn K et al.

Over 300,000 live births annually are affected by hemoglobinopathies worldwide. Of these, transfusion-dependent thalassemias (TDTs) result in severe phenotypes that significantly impact quality of life, shorten life expectancy, and incur high lifetime healthcare costs driven by recurrent transfusions and chelation therapy. Allogeneic hematopoietic cell transplantation (allo-HCT) is curative but limited by donor availability, regimen toxicity, graft-versus-host disease (GVHD), and transplant-related mortality. We present our single-center experience of TDT patients who underwent allo-HCT using a reduced-intensity conditioning (RIC) regimen (anti-thymocyte globulin, fludarabine, cyclophosphamide, total body irradiation) and posttransplant cyclophosphamide (PTCy)-based GVHD prophylaxis. Twenty-five consecutive children and young adults (ages 2-23 years, median 9) with TDT (beta-thalassemia major n=21, hemoglobin E-beta thalassemia n=3, hemoglobin D-beta thalassemia n=1) underwent HCT from July 2013 to November 2024. Bone marrow was the most common graft source (n=23, 92% of all patients), and haploidentical donors were the most common donor type (n=19, 76% of all patients). Neutrophil and platelet recovery occurred at median 21 days (range 13-38) and 26 days (range 16-88), respectively. Five patients (20%) developed grade I-II acute GVHD; none developed grade III-IV acute GVHD. Two (8%) developed mild chronic GVHD. At a median follow-up of 5.6 years (range 0.7-10), 5-year overall survival was 100%, transfusion-free survival 96%, and thalassemia-free-GVHD-free survival 96% - one patient experienced near-complete loss of donor chimerism with return of the TDT phenotype. Our RIC platform with best-available donor and PTCy-based GVHD prophylaxis significantly reduces post-HCT complications while providing durable transfusion independence, offering a proven, accessible, curative option for TDT.

PMID 43053710
阅读全文 →
PubMedThe Journal of pharmacology and experimental therapeutics2026-11-18

Post-marketing safety signals of rabbit antithymocyte globulin in FAERS and JADER, 2004-2024.

Xue Junling J, Yu Xihui X

Rabbit antithymocyte globulin (rATG) is used in transplant immunosuppression, but spontaneous reports may reveal safety signals not apparent in clinical studies. We analyzed rATG-indexed reports in FAERS and JADER from 2004 through 2024 using four disproportionality methods. We also explored reported-sex and age subgroups, time to onset, and alternative drug-role inclusion criteria. At the preferred-term level, 357 signals met the prespecified criteria in FAERS and 108 in. JADER, with 87 overlapping signals. Thrombotic microangiopathy and hemorrhagic cystitis were potential signals not identified in the labeling comparison. Vomiting and enterococcal sepsis showed different subgroup-specific reporting patterns by sex, and infection-related signals appeared among reports for patients aged ≥65 years. Overall median time to onset was 10 days in FAERS (1622 reports) and 25 days in JADER (1292 reports). The corresponding medians for infections and infestations were 11 and 30 days. These case-only analyses describe reporting associations and recorded onset intervals, not incidence, comparative clinical risk, or causality. The findings warrant confirmation in studies with control with confounding. SIGNIFICANCE STATEMENT: This analysis compares rATG reporting patterns in two spontaneous-reporting databases and identifies potential signals, including Thrombotic microangiopathy and hemorrhagic cystitis, that warrant further evaluation. The databases do not provide exposed-population denominators or complete follow-up. Accordingly, disproportionality and TTO findings are hypothesis-generating and do not quantify clinical incidence or establish causality.

PMID 43050894
阅读全文 →
PubMedJournal of molecular biology2026-11-18

Crystal Structure of Equine Coronavirus Main Protease in Complex with the inhibitor GC376-Considerations for Pan-Coronaviral Inhibitor Design.

Fischer Conrad C, Chen Pu P, van Belkum Marco J MJ, Van Oers Tayla J TJ et al.

Coronaviruses are highly transmissible pathogens that infect a broad range of hosts, with some causing severe illness in both humans and animals. Considerable research effort for the treatment of acute infection has been directed towards human coronaviral targets, including SARS-CoV-1/-2, MERS-CoV and other human coronaviruses. However, comparable study of related animal coronaviruses that may cross-over to humans is less prominent. Here we describe the cloning, isolation and purification of the genomically proposed equine coronavirus main protease (EqCoV-Mpro) and its C59S and C225S mutants to facilitate drug development. FDA-approved and investigational SARS-CoV-2 Mpro inhibitors, including GC376, inhibit EqCoV-Mpro with nanomolar potency. A surface-cysteine C59S mutation enabled the first X-ray co-crystal structure of EqCoV Mpro with GC376 at 2.0 Å. It reveals a deeper, more hydrophobic active site than related human and animal CoV Mpros, favoring compact inhibitors and informing future pan-coronaviral inhibitor design.

PMID 43051614
阅读全文 →
PubMedWomen's health (London, England)2026-11-18

Sex hormone-binding globulin during menopausal transition- associations with hormone therapy use, android fat, physical activity and eating behaviour.

Lankila Hannamari H, Hyvärinen Matti M, Kekäläinen Tiia T, Laakkonen Eija K EK et al.

BackgroundSex hormone-binding globulin SHBG is related to metabolic adversities, and menopausal women are at higher risk for increased abdominal adiposity associated with these detrimental changes. Health behaviours and the use of exogenous estrogen-containing therapy may contribute to metabolic health.ObjectivesTo investigate longitudinal changes in SHBG concentrations during the menopausal transition and their associations with hormone therapy use, android fat and health behaviours.DesignA longitudinal study included 298 Finnish women aged 47-55 years.MethodsData from a 4-year follow-up study ERMA and EsmiRs were used. SHBG was quantified using immunoassays, and android fat mass was measured with DXA. Health behaviours were assessed using accelerometer-measured physical activity and questionnaire-derived eating behaviour. Participants were categorized into PRE-POST group (pre- or perimenopausal at the baseline and postmenopausal at the follow-up, n = 148), PRE-PRE group (pre- or perimenopausal at both timepoints, n = 57) or POST-POST group (postmenopausal at both timepoints, n = 93). Linear mixed models were used to study the role of health behaviours and android fat mass as predictors of SHBG.ResultsThere were no differences at baseline SHBG levels between the groups. During the follow-up, SHBG increased in PRE-POST group (p = 0.036) among hormone therapy (HT) users, while there was a decrease in same group in HT non-users (p = 0.001). While higher android fat mass was associated with lower levels of SHBG in the sample with all participants, an increase of SHBG levels during the follow-up was detected independent of android fat mass and health behaviours in HT users.ConclusionsMenopausal estrogen-containing therapy may be a main driver for changes in SHBG concentrations during the menopausal transition. However, women not using hormone therapy, might benefit from regular eating styles to promote metabolic health during menopausal transition.

PMID 43049808
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多equine antithymocyte globulin